Clinical Edge Journal Scan

Early breast cancer: Rates of local recurrence higher with APBI than WBI


 

Key clinical point: Rates of local recurrence were higher with accelerated partial breast irradiation (APBI) than whole breast irradiation (WBI) in patients receiving breast-conservation treatment for early-stage breast cancer. Rate of distant metastasis, overall survival (OS), and disease-free survival (DFS) were similar.

Major finding: Patients receiving APBI vs. WBI had significantly higher rates of local recurrence (hazard ratio [HR], 1.46; P = .0002). DFS (HR, 1.11; P = .09), OS (HR, 1.11; P = .09), and distant metastasis (HR, 1.17; P = .11) were not different between the groups.

Study details : Findings are from a meta-analysis of 10 randomized controlled trials including 15,500 patients with early-stage breast cancer, including 7,758 patients in APBI and 7,742 patients in WBI groups.

Disclosures: No funding source was identified. The authors declared no conflicts of interest.

Source: Xiang X et al. Radiat Oncol. 2021 Feb 2. doi: 10.1186/s13014-021-01752-2 .

Recommended Reading

Genetic testing for breast and ovarian cancer: What has changed and what still needs to change?
MDedge Hematology and Oncology
Breast cancer mortality in under 40s resparks screening debate
MDedge Hematology and Oncology
Anthracycline-free neoadjuvant regimen safe, effective for TNBC
MDedge Hematology and Oncology
HER2+ metastatic breast cancer: Pyrotinib+capecitabine boosts PFS in PHOEBE
MDedge Hematology and Oncology
Early HER2+ early breast cancer: APHINITY follow-up confirms DFS benefit of add-on pertuzumab
MDedge Hematology and Oncology
cALND may be avoided by choosing BCT instead of mastectomy
MDedge Hematology and Oncology
No survival benefit of intensive screening for distant metastasis in breast cancer
MDedge Hematology and Oncology
Dose reduction may not necessarily reduce paclitaxel-induced neurotoxicity in breast cancer
MDedge Hematology and Oncology
Margetuximab bests trastuzumab in ERBB2-positive advanced breast cancer
MDedge Hematology and Oncology
HR+ early breast cancer: Palbociclib + adjuvant ET fails to improve survival
MDedge Hematology and Oncology